Drug
Nalbuphine ER (Haduvio™)
Status:
Phase 3
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Nalbuphine ER (Haduvio™) has a dual mechanism of action, acting as both an agonist (activator) to the kappa opioid receptor and as an antagonist (blocker) to the body’s mu opioid receptor. By targeting these receptors along the complete cough pathway, it has the potential to work regardless of whether the initial cough trigger originates in the lung or in the central nervous system.
Study Purpose
This is a randomized, double-blind, placebo-controlled study that evaluates the efficacy and safety of nalbuphine ER tablets for the treatment of chronic cough in participants with IPF.